Hikal Ltd.

NSE: HIKAL | BSE: 524735 | ISIN: INE475B01022 | Industry: Pharmaceuticals
| Falling Comet
262.1000 2.35 (0.90%)
NSE Sep 05, 2025 15:31 PM
Volume: 182.8K
 

logo
Hikal Ltd.
06 Nov 2020
262.10
0.90%
BP Wealth
INR3,368mn mainly driven by strong growth in the Pharmaceutical segment. On segmental performance: The crop protection segment de grew by 17.9% (YoY) to INR 926mn and 12.7% (YoY) due to deferment of orders worth INR400mn which is expected to be supplied largely in Q3FY21. Pharmaceutical segment revenue surged by 34.1% to INR 2,793mn led by strong volume off-take supported by new capacity at Bangalore unit which was commissioned late last year. Despite 554bps contraction in gross margin, EBITDA margin managed to improve by 58bps to18.8%, was 29bps above our estimate. EBITDA margin was supported by 11% (YoY) decline in employee cost and flat other expenses in the growing topline. EBIT margin of the Crop protection segment declined by 1044bps...
Hikal Ltd. has lost -26.84% in the last 6 Months
More from Hikal Ltd.
Recommended